Integrated NY-ESO-1 antibody and CD8(+) T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

Ipilimumab, a monoclonal antibody against cytotoxic T lymphocyte antigen 4 (CTLA-4), has been shown to improve survival in patients with advanced metastatic melanoma. It also enhances immunity to NY-ESO-1, a cancer/testis antigen expressed in a subset of patients with melanoma. To characterize the a...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Yuan, Jianda, Adamow, Matthew, Ginsberg, Brian A., Rasalan, Teresa S., Ritter, Erika, Gallardo, Humilidad F., Xu, Yinyan, Pogoriler, Evelina, Terzulli, Stephanie L., Kuk, Deborah, Panageas, Katherine S., Ritter, Gerd, Sznol, Mario, Halaban, Ruth, Jungbluth, Achim A., Allison, James P., Old, Lloyd J., Wolchok, Jedd D., Gnjatic, Sacha
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: National Academy of Sciences 2011
Pynciau:
Biological Sciences
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3189057/
https://ncbi.nlm.nih.gov/pubmed/21933959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1110814108
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg